These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 35390594)

  • 21. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
    Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
    J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS).
    Stamatellos VP; Papazisis G
    Curr Rev Clin Exp Pharmacol; 2023; 18(1):39-50. PubMed ID: 35418296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glatiramer acetate or IFN-β bridging therapy in women with relapsing multiple sclerosis planning a pregnancy.
    Hellwig K; Thiel S; Haben S; Ciplea AI; Kurzeja A
    Neurodegener Dis Manag; 2023 Aug; 13(4):223-234. PubMed ID: 37382065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: A 5 year prospective cohort study.
    Bawand R; Ghiasian M; Fathoallahi N; Moradi A
    Mult Scler Relat Disord; 2022 Jul; 63():103857. PubMed ID: 35597079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "No association between disease modifying treatment and fatigue in multiple sclerosis".
    Broch L; Flemmen HØ; Simonsen CS; Berg-Hansen P; Ormstad H; Brunborg C; Celius EG
    Mult Scler Relat Disord; 2023 Nov; 79():104993. PubMed ID: 37708819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple Sclerosis, Disease-Modifying Therapies, and Infections.
    Langer-Gould AM; Smith JB; Gonzales EG; Piehl F; Li BH
    Neurol Neuroimmunol Neuroinflamm; 2023 Nov; 10(6):. PubMed ID: 37813594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota.
    Pilotto S; Zoledziewska M; Fenu G; Cocco E; Lorefice L
    Mult Scler Relat Disord; 2023 May; 73():104671. PubMed ID: 37001407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
    Zhornitsky S; Greenfield J; Koch MW; Patten SB; Harris C; Wall W; Alikhani K; Burton J; Busche K; Costello F; Davenport JW; Jarvis SE; Lavarato D; Parpal H; Patry DG; Yeung M; Metz LM
    PLoS One; 2015; 10(4):e0123824. PubMed ID: 25867095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
    Landmeyer NC; Bürkner PC; Wiendl H; Ruck T; Hartung HP; Holling H; Meuth SG; Johnen A
    Neurology; 2020 Jun; 94(22):e2373-e2383. PubMed ID: 32430312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.
    Simpson-Yap S; Pirmani A; Kalincik T; De Brouwer E; Geys L; Parciak T; Helme A; Rijke N; Hillert JA; Moreau Y; Edan G; Sharmin S; Spelman T; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton RM; Salter A; Bebo B; Van der Walt A; Butzkueven H; Ozakbas S; Boz C; Karabudak R; Alroughani R; Rojas JI; van der Mei IA; Sciascia do Olival G; Magyari M; Alonso RN; Nicholas RS; Chertcoff AS; de Torres AZ; Arrambide G; Nag N; Descamps A; Costers L; Dobson R; Miller A; Rodrigues P; Prčkovska V; Comi G; Peeters LM
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36038263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late-onset multiple sclerosis in Iran: A report on demographic and disease characteristics.
    Ghadiri F; Sahraian MA; Razazian N; Ashtari F; Poursadeghfard M; Nabavi SM; Navardi S; Baghbanian SM; Shaygannejad V; Harirchian MH; Beladimoghadam N; Majdinasab N; Hosseini S; Azimi A; Kamali H; Sharifipour E; Hosseini Nejad Mir N; Bayati A; Nahayati MA; Heidari H; Mozhdehipanah H; Ghalyanchi Langroodi H; Jalali N; Ayoubi S; Asadollahzadeh E; Ebadi Z; Eskandarieh S; Naser Moghadasi A
    Mult Scler Relat Disord; 2023 Feb; 70():104493. PubMed ID: 36638768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis.
    Zaheer R; Amin R; Riddick L; Roy S; Wolff S; Nathanson A; Newsome S
    Mult Scler Relat Disord; 2023 Mar; 71():104575. PubMed ID: 36857853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis.
    Glasmacher SA; Kearns PK; Hassan Z; Connick P; Tauber S; Reetz K; Foley P; Chandran S;
    Mult Scler Relat Disord; 2022 Jul; 63():103837. PubMed ID: 35576728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What are the trends in the treatment of multiple sclerosis in recent studies? - A bibliometric analysis with global productivity during 1980-2021.
    Aykaç S; Eliaçık S
    Mult Scler Relat Disord; 2022 Dec; 68():104185. PubMed ID: 36183445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
    Lenz F; Harms L
    Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.